Latigo Biotherapeutics reports non-opioid drug cuts acute pain in Phase 2b trial

Latigo Biotherapeutics announced that its experimental non-opioid analgesic demonstrated a reduction in acute pain in a Phase 2b clinical trial.

The study results suggest the candidate may offer an alternative to existing opioid-based therapies and positions the company to challenge Vertex Pharmaceuticals’ approved pain medication, Journavx.

Latigo said it will now seek to confirm the findings in additional studies as it moves the program toward later-stage development.